Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Racial Variations in Mutational Profile in Newly Diagnosed Acute Myeloid Leukemia Patients

Tahsin Anwar, Mohammed Mian, Mahran Shoukier, Achuta K Guddati, Moinul Hossain, Ravindra Kolhe, MD PhD, Locke J. Bryan, Anand P Jillella, MD, Jorge E. Cortes, MD, Vamsi Kota, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-143329

Published: 2020

Journal Articles

Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience

Mahran Shoukier, Vamsi Kota, MD, Ravindra Kolhe, MD PhD, Locke J. Bryan, Anand P Jillella, MD, Jorge E. Cortes, MD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-135940

Published: 2020

Journal Articles

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Amir T. Fathi, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Eytan M. Stein, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Roland B. Walter, MD PhD MS, Anjali Advani, MD, Daniel J. DeAngelo, MD PhD, Tibor J. Kovacsovics, MD, Anand P Jillella, MD, Dale L. Bixby, MD PhD, Moshe Y Levy, MD, Megan M. O'Meara, MD, Phoenix Ho, MD, Anthony S. Stein, MD

Blood (2016) 128 (22): 591.

https://doi.org/10.1182/blood.V128.22.591.591

Published: 2016

Journal Articles

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

Dale L. Bixby, MD PhD, Anthony S. Stein, MD, Amir T. Fathi, MD, Tibor J. Kovacsovics, MD, Moshe Y Levy, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Anand P Jillella, MD, Farhad Ravandi, MD, Roland B. Walter, MD PhD MS, Eytan M. Stein, MD, Stefan Faderl, MD, Daniel J. DeAngelo, MD PhD, Phoenix Ho, MD, Megan M. O'Meara, MD, Jenna L Voellinger, PhD, Anjali Advani, MD

Blood (2016) 128 (22): 590.

https://doi.org/10.1182/blood.V128.22.590.590

Published: 2016

Journal Articles

Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience

H Jean Khoury, Leonard T Heffner, Jr., MD, Martha Arellano, MD, Anand P Jillella, MD, Vamsi K Kota, MD, Elliott F. Winton, MD

Blood (2015) 126 (23): 4045.

https://doi.org/10.1182/blood.V126.23.4045.4045

Published: 2015

Journal Articles

Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)

H. Jean Khoury, Vamsi Kota, M.B;B.S, Martha Arellano, MD, Stephanie L Bauer, ANP, Anand P Jillella, MD, Amelia Langston, MD, Zaid Al-Kadhimi, MD, Zachariah DeFilipp, MD, Audrey S Kim, RN, Elliott F. Winton, MD, John F Dipersio, MD PhD

Blood (2015) 126 (23): 1938.

https://doi.org/10.1182/blood.V126.23.1938.1938

Published: 2015

Journal Articles

Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma

Vamsi K Kota, MD, Amanda Redden Hathaway, MD, Bijal D. Shah, MD, Deniz Peker, MD, Ling Zhang, MD, David L. Jaye, MD, Martha Arellano, MD, H Jean Khoury, Anand P Jillella, MD, Elliott F. Winton, MD, Leonard T Heffner, Jr., MD, Uma Borate, MD

Blood (2015) 126 (23): 3762.

https://doi.org/10.1182/blood.V126.23.3762.3762

Published: 2015

Journal Articles

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

Amir T. Fathi, MD, Harry P Erba, MD PhD, Jeffrey E Lancet, MD, Eytan M Stein, Roland B. Walter, MD PhD MS, Daniel J. DeAngelo, MD PhD, Stefan Faderl, MD, Anand P Jillella, MD, Farhad Ravandi, MD, Anjali S. Advani, MD, Dale Bixby, MD PhD, Tibor J. Kovacsovics, MD, Megan M. O'Meara, MD, Dana A. Kennedy, PharmD, Anthony S. Stein, MD

Blood (2015) 126 (23): 454.

https://doi.org/10.1182/blood.V126.23.454.454

Published: 2015

Journal Articles

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Anthony S. Stein, MD, Roland B. Walter, MD PhD MS, Harry P Erba, MD PhD, Amir T. Fathi, MD, Anjali S. Advani, MD, Jeffrey E Lancet, MD, Farhad Ravandi, MD, Tibor J. Kovacsovics, MD, Daniel J. DeAngelo, MD PhD, Dale Bixby, MD PhD, Stefan Faderl, MD, Anand P Jillella, MD, Megan M. O'Meara, MD, Baiteng Zhao, PhD, Eytan M Stein

Blood (2015) 126 (23): 324.

https://doi.org/10.1182/blood.V126.23.324.324

Published: 2015

Journal Articles

Congestive Heart Failure (CHF) During Induction In ACUTE Promyelocytic Leukemia (APL) Patients

Arati Rani Chand, MBBS, Josh Simmons, MD, Farrukh Awan, MD, MS, Anand P. Jillella, MD, Ravindra B. Kolhe, MD, PhD, Vamsi Kota, M.B;B.S

Blood (2013) 122 (21): 3898.

https://doi.org/10.1182/blood.V122.21.3898.3898

Published: 2013

Journal Articles

A Successful Model To Decrease Early and Preventable Deaths In Acute Promyelocytic Leukemia (APL) Through The Use Of a Simplified Algorithm and Expert Support In Experienced As Well As Smaller Leukemia Treatment Centers In The US

Anand P. Jillella, MD, Ravindra B. Kolhe, MD, PhD, Farrukh Awan, MD, MS, Kavita Natrajan, MBBS, Vamsi Kota, M.B;B.S

Blood (2013) 122 (21): 5597.

https://doi.org/10.1182/blood.V122.21.5597.5597

Published: 2013

Journal Articles

A Network of Treatment Centers and Standardisation of Treatment Protocol Leads to Reduction in Mortality in Acute Promyelocytic Leukemia (APL)

Anand P. Jillella, MD, Farrukh Awan, MD, MS, Ravindra B. Kolhe, MD, PhD, Jeremy M Pantin, MB.BS., Devi D Morrison, Vamsi Kota, MBBS

Blood (2012) 120 (21): 4317.

https://doi.org/10.1182/blood.V120.21.4317.4317

Published: 2012

Journal Articles

Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Farrukh Awan, MD, MS, Samith Thomas Kochuparambil, Michael Craig, Aaron Cumpston, PharmD, Sonia Leadmon, BS, Kathy Watkins, David Deremer, Jeremy Pantin, MD, Vamsi Kota, MBBS, Anand P. Jillella, MD, Mehdi Hamadani, MD

Blood (2012) 120 (21): 4409.

https://doi.org/10.1182/blood.V120.21.4409.4409

Published: 2012

Journal Articles

Improving the Accuracy of BCR-ABL Transcript Quantitation: Pitfalls of Using a Common Standard for b3a2 and b2a2 Transcripts

Hanfang Zhang, MD, PhD, Linda Fletcher, Niren Patel, MBBS, Shanequa Bryant, Honglin Li, PhD, Ferdane Kutlar, MD, Anand P. Jillella, MD, Vamsi Kota, MBBS, Betsy Clair, Abdullah Kutlar, MD

Blood (2012) 120 (21): 4423.

https://doi.org/10.1182/blood.V120.21.4423.4423

Published: 2012

Journal Articles

Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Sayed Mehdi Hamadani, MD, Thomas Samith Kochuparambil, Salman Osman, MD, Ethan Speir, Michael Craig, MD, David Deremer, Aaron Cumpston, PharmD, Devi D Morrison, Sonia Leadmon, BS, Kristen Sterling, Pamela Bunner, BS, Meghan Sterrett, Vamsi Kota, MBBS, Anand P. Jillella, MD, Farrukh T Awan, MD, MS

Blood (2011) 118 (21): 313.

https://doi.org/10.1182/blood.V118.21.313.313

Published: 2011

Journal Articles

Defining Treatment Paradigms for BK Virus-Induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting

Devi D Morrison, Samith Thomas Kochuparambil, David Deremer, Ethan Speir, Kristen Sterling, Meghan Sterrett, Vamsi Kota, MBBS, Anand P. Jillella, MD, Farrukh T Awan, MD, MS

Blood (2011) 118 (21): 4468.

https://doi.org/10.1182/blood.V118.21.4468.4468

Published: 2011

Journal Articles

Effect of Nilotinib (NIL) on Molecular Response in Chronic Myelogenous Leukemia - Chronic Phase (CML-CP) Patients (pts) with a Suboptimal Molecular Response to Imatinib (IM)–ENABL Study Update

Sikander Ailawadhi, MD, Carole B. Miller, MD, Anand P. Jillella, MD, Nebu Koshy, MD, Brian Tudor, MD, Luke P. Akard, MD, Solveig G. Ericson, MD- PhD, Felice P. Lin, PharmD, Jerald P. Radich, MD, Daniel J. DeAngelo, MD, PhD

Blood (2011) 118 (21): 2771.

https://doi.org/10.1182/blood.V118.21.2771.2771

Published: 2011

Journal Articles

Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Pierre Fenaux, MD, PhD, Daniel J DeAngelo, MD, PhD, Guillermo Garcia-Manero, MD, Michael Lübbert, MD, PhD, Anand P. Jillella, MD, Mikkael A. Sekeres, MD, MS, Ivo J. Winiger, MD, Margaret Squier, MD, PhD, Xiaodong Li, PhD, Oliver G. Ottmann, M.D.

Blood (2010) 116 (21): 4957.

https://doi.org/10.1182/blood.V116.21.4957.4957

Published: 2010

Journal Articles

Utility of Plerixafor In Addition to Chemotherapy and G-CSF Mobilization Regimens

Farrukh Awan, MD, MS, David Deremer, Elaine Mebel, Samith Thomas Kochuparambil, Anand P. Jillella, MD

Blood (2010) 116 (21): 4443.

https://doi.org/10.1182/blood.V116.21.4443.4443

Published: 2010

Journal Articles

Potential Pitfalls In Quantitative Real-Time PCR for Molecular Monitoring of BCR-ABL In the Management of CML.

Hanfang Zhang, MD, PhD, Niren Patel, MBBS, Ferdane Kutlar, MD, Anand P. Jillella, MD, Celalettin Ustun, MD, Leigh G Wells, MSN, RN, FNP-BC, Betsy Clair, Abdullah Kutlar, MD

Blood (2010) 116 (21): 1228.

https://doi.org/10.1182/blood.V116.21.1228.1228

Published: 2010

NARROW

Racial Variations in Mutational Profile in Newly Diagnosed Acute Myeloid Leukemia Patients

Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience

Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)

Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Congestive Heart Failure (CHF) During Induction In ACUTE Promyelocytic Leukemia (APL) Patients

A Successful Model To Decrease Early and Preventable Deaths In Acute Promyelocytic Leukemia (APL) Through The Use Of a Simplified Algorithm and Expert Support In Experienced As Well As Smaller Leukemia Treatment Centers In The US

A Network of Treatment Centers and Standardisation of Treatment Protocol Leads to Reduction in Mortality in Acute Promyelocytic Leukemia (APL)

Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Improving the Accuracy of BCR-ABL Transcript Quantitation: Pitfalls of Using a Common Standard for b3a2 and b2a2 Transcripts

Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Defining Treatment Paradigms for BK Virus-Induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting

Effect of Nilotinib (NIL) on Molecular Response in Chronic Myelogenous Leukemia - Chronic Phase (CML-CP) Patients (pts) with a Suboptimal Molecular Response to Imatinib (IM)–ENABL Study Update

Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Utility of Plerixafor In Addition to Chemotherapy and G-CSF Mobilization Regimens

Potential Pitfalls In Quantitative Real-Time PCR for Molecular Monitoring of BCR-ABL In the Management of CML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only